Design of a Bayesian adaptive phase 2 proof‐of‐concept trial for BAN2401, a putative disease‐modifying monoclonal antibody for the treatment of Alzheimer's disease

Andrew Satlin, Donald A. Berry, Scott Berry et al.|Alzheimer s & Dementia Translational Research & Clinical Interventions|2016

Cited by 87